Ironwood Pharmaceuticals (IRWD) Q3 2024 Earnings
IRWD·Reported November 7, 2024·Before market open
Ironwood Pharmaceuticals reported Q3 2024 revenue of $91.6M, missed analyst consensus of $92.5M by $888.0K. Diluted EPS came in at $0.02, missed the $0.08 consensus by $0.06.
Revenue
$91.6Mmissed by $888.0K
Consensus: $92.5MDiluted EPS
$0.02missed by $0.06
Consensus: $0.08
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about Ironwood Pharmaceuticals's Q3 2024 earnings report.
Ironwood Pharmaceuticals (IRWD) reported Q3 2024 earnings on November 7, 2024 before market open.
Ironwood Pharmaceuticals reported revenue of $91.6M and diluted EPS of $0.02 for Q3 2024.
Revenue missed the consensus estimate of $92.5M by $888.0K. EPS missed the consensus estimate of $0.08 by $0.06.
You can read the 10-Q periodic report (0001558370-24-014909) directly on SEC EDGAR. The filing index links above go to sec.gov.